Compare AU
Compare JREG vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Jpmorgan Gl Res En In Eq Active ETF (Managed Fund) (JREG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
JREG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 80 |
Median incremental investment | $4,496.75 | $620.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $6,473.55 | $1,325.53 |
Average age group | > 35 | > 35 |
Key Summary
JREG | CURE | |
|---|---|---|
Strategy | JREG.AX was created on 2015-05-05 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. To achieve a long-term return in excess of the benchmark, | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Apple Inc (5.22 %) NVIDIA Corp (5.02 %) Microsoft Corp (4.60 %) | Neurocrine Biosciences Inc (2.68 %) Alnylam Pharmaceuticals Inc (2.53 %) Insmed Inc (2.44 %) |
Top 3 industries | Information Technology (49.69 %) Other (22.31 %) Consumer Discretionary (15.87 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (73.29 %) Japan (4.97 %) United Kingdom of Great Britain and Northern Ireland (4.05 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.3 % | 0.45 % |
Key Summary
JREG | CURE | |
|---|---|---|
Issuer | JPMorgan | Global X |
Tracking index | MSCI World ex Australia Index - AUD - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.3 % | 0.45 % |
Price | $78.95 | $50.44 |
Size | N/A | $34.226 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.67 % | 4.24 % |
Market | ASX | ASX |
First listed date | 09/11/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
JREG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 80 |
Median incremental investment | $4,496.75 | $620.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $6,473.55 | $1,325.53 |
Average age group | > 35 | > 35 |
Pros and Cons
JREG | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
JREG | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |